Wall Street brokerages predict that ITUS Corporation (NYSE:ANIX) will report earnings per share (EPS) of ($0.13) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ITUS’s earnings. ITUS reported earnings per share of ($0.23) during the same quarter last year, which indicates a positive year over year growth rate of 43.5%. The business is expected to issue its next earnings results on Wednesday, March 11th.
According to Zacks, analysts expect that ITUS will report full year earnings of ($0.49) per share for the current financial year. For the next financial year, analysts expect that the company will report earnings of ($0.47) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for ITUS.
Several brokerages have commented on ANIX. Zacks Investment Research raised ITUS from a “hold” rating to a “buy” rating and set a $3.50 price target on the stock in a research report on Wednesday, January 1st. B. Riley cut their price target on ITUS from $11.25 to $8.00 and set a “buy” rating for the company in a report on Monday, December 30th.
NYSE:ANIX traded up $0.04 during mid-day trading on Friday, hitting $3.27. 32,012 shares of the company’s stock traded hands, compared to its average volume of 57,732. The firm has a 50 day moving average of $3.45 and a two-hundred day moving average of $3.71. ITUS has a 12 month low of $2.74 and a 12 month high of $5.47.
ITUS Company Profile
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Featured Article: Quantitative Easing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ITUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ITUS and related companies with MarketBeat.com's FREE daily email newsletter.